Comparison
While PT-141 is FDA-approved for treatment of hypoactive sexual desire disorder in premenopausal women and is studied for sexual dysfunction in other populations, increasing sexual desire via CNS melanocortin pathways42101, Thymosin Beta-4 promotes wound healing, angiogenesis, and tissue regeneration in preclinical models via effects on cytoskeleton dynamics, cell migration, and anti-apoptotic pathways25579.
While PT-141 works as the synthetic melanocortin receptor agonist bremelanotide, an analog of α-MSH that activates central MC3R and MC4R to modulate neuronal circuits governing sexual desire and arousal3242101, Thymosin Beta-4 is an endogenous 43-amino-acid actin-sequestering peptide that maintains a pool of G-actin monomers and regulates actin polymerization, thereby influencing cell migration, proliferation, and differentiation25579.
PT-141 is 7 amino acids long, whereas Thymosin Beta-4 is longer as it has a length of 43 amino acids. PT-141 is made up of a sequence of sequence data not available in the current dataset. Thymosin Beta-4 is made up of a sequence of Serine, Aspartic acid, Lysine, Proline, Aspartic acid, Methionine, Alanine, Glutamic acid, Isoleucine, Glutamic acid, Lysine, Phenylalanine, Aspartic acid, Lysine, Serine, Lysine, Lysine, Proline, Aspartic acid, Methionine, Alanine, Glutamic acid, Glutamic acid, Lysine, Phenylalanine, Aspartic acid, Lysine, Lysine, Glutamic acid, Lysine, Lysine, Glutamic acid, Glutamic acid, Alanine, Glutamic acid, Asparagine, Glutamic acid, Glutamic acid, Lysine, Glutamic acid, Serine.
PT-141
POMC
Thymosin Beta-4
TMSB4X